Off the wire
• Forty five sentenced for deadly Shenzhen landslide  • DPRK condemns U.S. test launch of ICBM  • (BRF) China publishes book about the Belt and Road Initiative in 14 languages  • ASEAN+3 finance chiefs discuss economy, cooperation in Japan  • 4th LD-Writethru: China's homegrown jumbo passenger jet takes to the sky  • Scientists stress interventions to contain Africa's armyworm invasion  • Singapore firm buys Manchester hotel popular with football stars  • Syngenta's shareholders accept ChemChina merger offer  • Interest rate cap law to hurt Kenya's economic growth: IMF  • Kenya to roll out literacy strategy to boost capital markets penetration  
You are here: 　 Home

European Medicines Agency launches guide on biosimilar medicines

Xinhua, May 5, 2017 Adjust font size:

The European Medicines Agency (EMA) and the European Commission on Friday launched an information guide on biosimilar medicines for the better understanding of these medicines.

The guide was aimed to offer scientific and regulatory reference to healthcare professionals about the use of biosimilars.

Biosimilars are medicines that are similar to authorized biological medicines in all essential aspects. EMA and the Commission worked with scientific experts from the EU to address questions in this area from healthcare professionals.

The EU approved the first biosimilar medicine in 2006. Since then, the agency's Committee for Medicinal Products for Human Use has recommended 28 biosimilars for use in the bloc, said the EMA.

Evidence showed that biosimilars approved in the bloc are safe and effective as other biological medicines, it said. Endit